Kinetics of Tumour Necrosis Factor-alpha, Soluble Tumour Necrosis Factor Receptors, Interleukin 1-beta and Its Receptor Antagonist During Serious Infections

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 1994 Jan 1

PMID 7821299

Citations 10

Authors

M van Deuren

Affiliations

Soon will be listed here.

Abstract

Tumour necrosis factor-alpha (TNF) and interleukin-1 beta (IL-1 beta) are the central mediators in the genesis of sepsis. The proinflammatory effects of these cytokines are counteracted in vivo by natural inhibitors. Soluble TNF receptors (sTNFR) are shed upon inflammatory stimuli such as IL-1 beta and TNF itself. Circulating TNF can be complexed by these receptors, thus preventing TNF from binding to effector cells. The binding of IL-1 beta to its receptor can be blocked by high concentrations of interleukin-1 receptor antagonist (IL-1Ra), which is produced and released upon nearly the same stimuli as IL-1 beta. This review presents some aspects of the kinetic behaviour of native sTNFR and of the production of native IL-1Ra during severe infections. It appears that in fulminant septicaemia, the plasma concentration of TNF is increased only transiently, during the very early stage of the infection. The concentration of sTNFR, in contrast, remains elevated much longer, probably due to a slower clearance. During the acute stage of severe infectious diseases, peripheral blood cells cannot be stimulated to produce IL-1 beta. The production of IL-1 Ra, in contrast, is not affected. Thus, the kinetic behaviour and regulation of TNF and IL-1 beta, is different from that of their antiinflammatory counterparts.

Citing Articles

Transcriptomic changes in the large organs in lethal meningococcal shock are reflected in a porcine shock model.

Brusletto B, Hellerud B, Olstad O, Ovstebo R, Brandtzaeg P Front Cell Infect Microbiol. 2022; 12:908204.

PMID: 36034711 PMC: 9413276. DOI: 10.3389/fcimb.2022.908204.

Involvement of Inflammasome Components in Kidney Disease.

Aranda-Rivera A, Srivastava A, Cruz-Gregorio A, Pedraza-Chaverri J, Mulay S, Scholze A Antioxidants (Basel). 2022; 11(2).

PMID: 35204131 PMC: 8868482. DOI: 10.3390/antiox11020246.

Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation.

Haberecht-Muller S, Kruger E, Fielitz J Biomolecules. 2021; 11(9).

PMID: 34572540 PMC: 8468834. DOI: 10.3390/biom11091327.

Sepsis-Induced Immunosuppression in Neonates.

Hibbert J, Currie A, Strunk T Front Pediatr. 2018; 6:357.

PMID: 30555806 PMC: 6281766. DOI: 10.3389/fped.2018.00357.

Deletion of Nlrp3 protects from inflammation-induced skeletal muscle atrophy.

Huang N, Kny M, Riediger F, Busch K, Schmidt S, Luft F Intensive Care Med Exp. 2017; 5(1):3.

PMID: 28097512 PMC: 5241267. DOI: 10.1186/s40635-016-0115-0.

References

Vannier E, Miller L, Dinarello C . Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A. 1992; 89(9):4076-80. PMC: 525635. DOI: 10.1073/pnas.89.9.4076. View

Girardin E, Roux-Lombard P, Grau G, Suter P, Gallati H, Dayer J . Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology. 1992; 76(1):20-3. PMC: 1421754. View

Hesse D, Tracey K, Fong Y, Manogue K, Palladino Jr M, Cerami A . Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988; 166(2):147-53. View

Havell E . Production of tumor necrosis factor during murine listeriosis. J Immunol. 1987; 139(12):4225-31. View

Olsson I, Gullberg U, Lantz M, Peetre C . A tumor necrosis factor binding protein (TNF-BP)-physiological antagonist of TNF. Biotherapy. 1991; 3(2):159-65. DOI: 10.1007/BF02172088. View

Beutler B, Milsark I, Cerami A . Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985; 229(4716):869-71. DOI: 10.1126/science.3895437. View

Blanchard D, Djeu J, Klein T, Friedman H, Stewart 2nd W . Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol. 1988; 43(5):429-35. DOI: 10.1002/jlb.43.5.429. View

Granowitz E, Santos A, Poutsiaka D, Cannon J, Wilmore D, Wolff S . Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet. 1991; 338(8780):1423-4. DOI: 10.1016/0140-6736(91)92725-h. View

Dinarello C . The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis. 1991; 163(6):1177-84. DOI: 10.1093/infdis/163.6.1177. View

10.

van der Poll T, Buller H, ten Cate H, Wortel C, Bauer K, van Deventer S . Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990; 322(23):1622-7. DOI: 10.1056/NEJM199006073222302. View

11.

Tracey K, Fong Y, Hesse D, Manogue K, Lee A, Kuo G . Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987; 330(6149):662-4. DOI: 10.1038/330662a0. View

12.

van Deuren M, Santman F, van Dalen R, Sauerwein R, Span L, van der Meer J . Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis. 1992; 15(3):424-30. DOI: 10.1093/clind/15.3.424. View

13.

Cannon J, Tompkins R, Gelfand J, Michie H, Stanford G, van der Meer J . Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990; 161(1):79-84. DOI: 10.1093/infdis/161.1.79. View

14.

van Deuren M, van der Ven-Jongekrijg J, Demacker P, Bartelink A, van Dalen R, Sauerwein R . Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis. 1994; 169(1):157-61. DOI: 10.1093/infdis/169.1.157. View

15.

van Deuren M, Dofferhoff A, van der Meer J . Cytokines and the response to infection. J Pathol. 1992; 168(4):349-56. DOI: 10.1002/path.1711680403. View

16.

Suffredini A, Fromm R, Parker M, Brenner M, Kovacs J, Wesley R . The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989; 321(5):280-7. DOI: 10.1056/NEJM198908033210503. View

17.

Bemelmans M, Gouma D, Buurman W . Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol. 1993; 150(5):2007-17. View

18.

Okusawa S, Gelfand J, Ikejima T, Connolly R, Dinarello C . Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988; 81(4):1162-72. PMC: 329645. DOI: 10.1172/JCI113431. View

19.

Van Zee K, Kohno T, FISCHER E, Rock C, Moldawer L, Lowry S . Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992; 89(11):4845-9. PMC: 49184. DOI: 10.1073/pnas.89.11.4845. View

20.

Michie H, Manogue K, Spriggs D, Revhaug A, ODwyer S, Dinarello C . Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988; 318(23):1481-6. DOI: 10.1056/NEJM198806093182301. View